Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene Plus Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)

Standard therapy in the form of home quarantine for 2 weeks along with social distancing and personal hygiene

CoVID-19

Tablet HCQ 400 mg q 12 hourly on day one followed by 400 mg once weekly for 3 weeks (total cumulative dose of 2000 mg)

Home quarantine for 2 weeks plus social distancing plus personal hygiene

Standard therapy

Post Graduate Institute of Medical Education and Research (PGIMER)

Post Graduate Institute of Medical Education and Research

Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19

Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19 in Asymptomatic Individual at Risk for SARS-CoV-2 Infection-A Open Level Control Clinical Trial

Symptomatic individual with RTPCR positive for SARS-CoV-2 will be defined as confirmed COVID-19 case

Symptomatic individual with RTPCR negative for SARS-CoV-2 will be defined as probable COVID-19 case.

Any adverse reaction related to Hydroxychloroquine

Data will be shared with the concerned authority and Institutional Ethics committee as and when required.

Deba Prasad Dhibar

Assistant Professor

Postgraduate Institute of Medical Education and Research

Parainfluenza Infection

DAS181

Placebo

DAS181 in Patients With Parainfluenza

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of DAS181 in Patients With Parainfluenza Infection

National Institute of Allergy and Infectious Diseases (NIAID)

Participants will be studied in three cohorts:
Healthy seropositive children 3 years up to 6 years
Healthy seropositive toddlers 12 months up to 24 months
Healthy seronegative toddlers 12 months up to 24 months.
Each cohort will receive Sendai virus vaccine.

Parainfluenza

Respiratory Viral Infections

Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10^5 to 5 x 10^7 EID(50) units.

Sendai virus vaccine

Croup Study Volunteer Recruitment Information

croup/fiebre

Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19

DAS181 in Patients With Parainfluenza

A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and Toddlers

La base de datos de hierbas medicinales más completa respaldada por la ciencia